Disability News and Research

RSS

Data from Phase III clinical trial of TYSABRI presented at ECTRIMS

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced data presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) showing the potential of TYSABRI® (natalizumab) to redefine successful multiple sclerosis (MS) therapy.

14 Sep 2009

Extremity Trauma Clinical Research Consortium for treating major limb injuries

The Johns Hopkins Bloomberg School of Public Health has been awarded $18.4 million by the Orthopaedic Extremity Trauma Research Program (OETRP) of the U.S. Department of Defense to establish an Extremity Trauma Clinical Research Consortium.

14 Sep 2009

Results further support the benefits of TYSABRI for multiple sclerosis patients

Biogen Idec and Elan Corporation, plc (NYSE: ELN) today announced six-month results of an ongoing, one-year longitudinal, observational, patient-reported outcomes study showing multiple sclerosis (MS) patients taking TYSABRI- (natalizumab) experienced an improvement in both their physical function and psychological well-being.

14 Sep 2009

Obama's interview on health and fitness priorities to be published in a health magazine

President Barack Obama and First Lady Michelle Obama speak candidly about health and fitness priorities for the country and their family in exclusive interviews that will appear in the October 2009 issues of Men’s Health and Women’s Health, respectively. The October issues hit newsstands on Tuesday, September 15.

14 Sep 2009

Scientific program to treat and prevent mental disorders

Mental disorders are a global problem and represent one of the biggest challenges for health care systems. In the world, there are some 500 million people suffering from mental disorders, and in the European Union, mental disorders range as one of the leading causes of disease burden.

14 Sep 2009

Phase 2 MS clinical trial data continues to show durable reductions in relapse rate

Genzyme Corporation reported today that four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab.

14 Sep 2009

APHA calls for comprehensive health care reform affordable to all Americans

"According to new Census Bureau data released today, there are now more than 46 million Americans who do not have health coverage. And alarmingly, things are only getting worse.

11 Sep 2009

Biomarkers for rapid identification of treatment effectiveness in major depression

Now, based on the final results of a nationwide study led by UCLA, clinicians may be able to accurately predict within a week whether a particular drug will be effective by using a non-invasive test that takes less than 15 minutes to administer. The test will allow physicians to quickly switch patients to a more effective treatment, if necessary.

11 Sep 2009

Therapeutic principles of monoclonal antibodies

Professor Joachim R. Kalden, Member of the Department for Molecular Immunology, Nikolaus-Fiebiger-Zentrum, University Medical School Erlangen-Nuremberg, presents therapeutic principles based on monoclonal antibodies.

10 Sep 2009

Federal judge finds New York State discriminated against mentally ill

The New York Times reports: "New York State discriminated against thousands of mentally ill people in New York City by leaving them in privately run adult homes, which effectively replaced state-run psychiatric hospitals more than a generation ago but turned out to be little more than institutions themselves, a federal judge ruled on Tuesday."

10 Sep 2009

New television program to raise awareness about cardiovascular diseases in women

Research shows that 80 percent of cardiac events in women could be prevented if women make the right choices for their hearts, involving diet, exercise and abstinence from smoking.

9 Sep 2009

Phase 3 clinical trials of BHR-100 infusion to be initiated by BHR Pharma

BHR Pharma, LLC (BHR) announced today that it will initiate a global, Phase 3, multi-center pivotal trial (www.synapse-trial.com) to evaluate the effectiveness of its proprietary BHR-100 intravenous progesterone infusion product as a neuroprotective agent for treating severe traumatic brain injury (TBI) patients in early 2010.

9 Sep 2009

EDS signs $8.1 million contract with U.S. DoD Military Health System

EDS, an HP company, today announced it has signed an $8.1 million, 12-month add-on contract with the U.S. Department of Defense (DoD) Military Health System to make technical enhancements to several Defense Health Information Management Systems (DHIMS).

8 Sep 2009

Opexa Therapeutics releases Phase IIb TERMS clinical study results

Opexa Therapeutics, Inc., a company developing Tovaxin, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced results from further analysis of the double-blind, placebo-controlled, 52-week Phase IIb TERMS clinical study of 150 patients with Relapsing Remitting MS (RRMS).

8 Sep 2009

$geneX combined with Mesenchymal stem cells for treating fracture$

geneX combined with Mesenchymal stem cells for treating fracture

Professor James B. Richardson of the Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, UK has been carrying out pioneering work combining geneX with selected and culture expanded Mesenchymal stem cells to treat fracture non-unions.

7 Sep 2009

Early schizophrenia symptoms include unusually high CA1 subfield activity

In the first functional magnetic resonance imaging (fMRI) study of its kind, neurologists and psychiatrists at Columbia University have identified an area of the brain involved in the earliest stages of schizophrenia and related psychotic disorders.

7 Sep 2009

People with genetic risk of bowel cancer decline genetic testing

An Australian study of families with genetic risk of bowel cancer has found that 50 percent of participants declined genetic testing when informed of insurance implications.

7 Sep 2009

Book for young life insurance beneficiaries

Anthem Life kicks off Life Insurance Awareness Month by enhancing the support services already available to its group life insurance beneficiaries by offering a new book to help children who are affected by the loss of a loved one - The Healing Book: Facing the Death and Celebrating the Life of Someone You Love (written by Ellen Sabin and published by Watering Can Press).

5 Sep 2009

Health Net's ECHO kit to help military families maximize the health care benefits

Health Net Federal Services, LLC, the government operations division of Health Net, Inc. (NYSE:HNT), today announced its newly developed Extended Care Health Option (ECHO) kit for service members and their families in the TRICARE North Region, designed to provide user-friendly, educational information to enhance understanding of the ECHO program.

5 Sep 2009

Yoga reduces back pain and fights depression

People with chronic low-back problems who do yoga also do better at overcoming pain and depression than people treated conventionally for back pain, a West Virginia University study funded by the National Institutes of Health shows.

5 Sep 2009